Skip to main content
. 2016 May 30;18(2):221–228. doi: 10.22074/cellj.2016.4317

Fig.2.

Fig.2

llustrated protocol of mouse embryonic stem cells (mESCs) treatment with peroxisome proliferator-activated receptor γ (PPARγ) agonist [Rosiglitazone (Rosi)] and antagonist [GW9662 (GW)] during cardiac progenitor cells (CPCs) formation (within the five day interval). qPCR; Quantitative real-time polymerase chain reaction and FCS; Fetal calf serum.